OCRA is pleased to award research prizes to Dr. Ursula Matulonis and Dr. Pradeep Chaluvally-Raghavan, two investigators doing groundbreaking and important work in the field of ovarian cancer research. OCRA’s … Continued
A recent study, funded in part by OCRA, has shed new light on how the most common subtype of ovarian cancer develops and metastasizes, by identifying a key molecule that … Continued
As immunotherapies have seen rising success in treating several other cancers, researchers are hard at work uncovering why immunotherapy for ovarian cancer has, so far, proven ineffective. In a study … Continued
Dr. Melica Brodeur, of Memorial Sloan Kettering Cancer Center, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “Exploiting SMARCA4 Alterations for New Therapeutics in Ovarian Cancer,” … Continued
“We are truly in the Golden Age, the Renaissance, if you will, of care for people with ovarian cancer. So much is happening.” Dr. Stephanie Blank Though there is still … Continued
Dr. Amrita Salvi, of University of Illinois at Chicago, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “Investigating the Mechanism of Action of PHY34 in HGSOC,” … Continued
Dr. Zelei Yang, of Dana Farber Cancer Institute, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “Re-engaging the Anti-tumor Immune Response Against Ovarian Cancer,” Dr. Yang … Continued
Dr. Gamze Bildik Elcik, postdoctoral fellow in the Department of Experimental Therapeutics at MD Anderson Cancer Center, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “DIRAS3 … Continued
Recent research published in JNCCN–Journal of the National Comprehensive Cancer Network has shown that there are clear disparities when it comes to which ovarian cancer patients are receiving treatment in accordance with … Continued
Dr. Erin Wesley, of University of Minnesota Twin Cities, is a 2022 recipient of OCRA’s Mentored Investigator Grant. With her project, “Impact of Cytomegalovirus and Inflammation on NK Cells in … Continued
In exciting treatment news, the Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (trade name Elahere, made by Immunogen, Inc.), for adults with folate receptor alpha … Continued
“I don’t believe we can maximize our impact on ovarian cancer without embracing opportunities in other gynecologic cancers.” Dr. David Huntsman David Huntsman, MD, FRCPC, FCCMG, understands the field of … Continued
Get email updates about research news, action alerts, and ways to join the fight.
